Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 481–490 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 481

    Medicine slug
    atogepant
    Medicine name
    Atogepant
    Enzyme or transporter
    OCT1
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Atogepant is a weak inhibitor of OATP1B1, OATP1B3, OCT1, and MATE1.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Atogepant is a weak inhibitor of OATP1B1, OATP1B3, OCT1, and MATE1.

  2. Projected row 482

    Medicine slug
    atogepant
    Medicine name
    Atogepant
    Enzyme or transporter
    OCT2
    Role
    SUBSTRATE
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Atogepant is not a substrate of OAT3, OCT2, or MATE1.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Atogepant is not a substrate of OAT3, OCT2, or MATE1.

  3. Projected row 483

    Medicine slug
    atogepant
    Medicine name
    Atogepant
    Enzyme or transporter
    P-GP
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    6
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      BCRP/OATP/P-gp Inhibitors Co-administration of QULIPTA with single dose rifampin, an OATP inhibitor, increased atogepant AUC by 2.85-fold and C max by 2.23-fold in healthy subjects [see Drug Interactions ( 7.3 )] .
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Co-administration of QULIPTA with quinidine, a P-gp inhibitor, increased atogepant AUC by 26% and C max by 4% in healthy subjects.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      BCRP/OATP/P-gp Inhibitors Co-administration of QULIPTA with single dose rifampin, an OATP inhibitor, increased atogepant AUC by 2.85-fold and C max by 2.23-fold in healthy subjects [see Drug Interactions ( 7.3 )] .
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Co-administration of QULIPTA with quinidine, a P-gp inhibitor, increased atogepant AUC by 26% and C max by 4% in healthy subjects.
    5. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Coadministration of atogepant with BCRP and/or P-gp inhibitors is not expected to increase the exposure of atogepant.
    6. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Atogepant is not an inhibitor of P-gp, BCRP, OAT1, OAT3, NTCP, BSEP, MRP3, or MRP4 at clinically relevant concentrations.
    7. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      The changes in atogepant exposure when co-administered with P-gp inhibitors are not expected to be clinically significant.
    8. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Coadministration of atogepant with BCRP and/or P-gp inhibitors is not expected to increase the exposure of atogepant.
    9. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Atogepant is not an inhibitor of P-gp, BCRP, OAT1, OAT3, NTCP, BSEP, MRP3, or MRP4 at clinically relevant concentrations.
    10. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      The changes in atogepant exposure when co-administered with P-gp inhibitors are not expected to be clinically significant.

  4. Projected row 484

    Medicine slug
    atogepant
    Medicine name
    Atogepant
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      The observed change in atogepant exposures is a composite effect of inhibition of OATP1B1 and OATP1B3 transporters as well as induction of CYP3A4 and P-gp.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      The observed change in atogepant exposures is a composite effect of inhibition of OATP1B1 and OATP1B3 transporters as well as induction of CYP3A4 and P-gp.

  5. Projected row 485

    Medicine slug
    atogepant
    Medicine name
    Atogepant
    Enzyme or transporter
    P-GP
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Transporters Atogepant is a substrate of P-gp, BCRP, OATP1B1, OATP1B3, and OAT1.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:8c8ab8f4-32bd-497a-befa-70c8a51d8d52 (opens source in a new tab)

      Atogepant label

      Version not recorded · Effective date not recorded

      Transporters Atogepant is a substrate of P-gp, BCRP, OATP1B1, OATP1B3, and OAT1.

  6. Projected row 486

    Medicine slug
    atomoxetine
    Medicine name
    Atomoxetine
    Enzyme or transporter
    CYP2C19
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in Ems and 45% of atomoxetine concentration in PMs).
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in Ems and 45% of atomoxetine concentration in PMs).

  7. Projected row 487

    Medicine slug
    atomoxetine
    Medicine name
    Atomoxetine
    Enzyme or transporter
    CYP2D6
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13) ].
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13) ].

  8. Projected row 488

    Medicine slug
    atomoxetine
    Medicine name
    Atomoxetine
    Enzyme or transporter
    CYP2D6
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    11
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronidation.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs.
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Metabolism and elimination - Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway.
    4. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Laboratory tests are available to identify CYP2D6 PMs.
    5. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Atomoxetine did not inhibit or induce the CYP2D6 pathway.
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Cardiac Electrophysiology — The effect of atomoxetine hydrochloride on QTc prolongation was evaluated in a randomized, double-blinded, positive-(moxifloxacin 400 mg) and placebo-controlled, cross-over study in healthy male CYP2D6 poor metabolizers.
    7. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronidation.
    8. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs.
    9. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Metabolism and elimination - Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway.
    10. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Laboratory tests are available to identify CYP2D6 PMs.
    11. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)

      Atomoxetine label

      Version not recorded · Effective date not recorded

      Atomoxetine did not inhibit or induce the CYP2D6 pathway.

  9. Projected row 489

    Medicine slug
    atorvastatin
    Medicine name
    Atorvastatin
    Enzyme or transporter
    BCRP
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:09c6c750-ae05-459f-83e8-4a9e4fd85212 (opens source in a new tab)

      Atorvastatin label

      Version not recorded · Effective date not recorded

      Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:09c6c750-ae05-459f-83e8-4a9e4fd85212 (opens source in a new tab)

      Atorvastatin label

      Version not recorded · Effective date not recorded

      Atorvastatin is also identified as a substrate of the efflux transporter BCRP, which may limit the intestinal absorption and biliary clearance of atorvastatin.

  10. Projected row 490

    Medicine slug
    atorvastatin
    Medicine name
    Atorvastatin
    Enzyme or transporter
    OATP1B1
    Role
    SUBSTRATE
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:09c6c750-ae05-459f-83e8-4a9e4fd85212 (opens source in a new tab)

      Atorvastatin label

      Version not recorded · Effective date not recorded

      Drug Interactions Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:09c6c750-ae05-459f-83e8-4a9e4fd85212 (opens source in a new tab)

      Atorvastatin label

      Version not recorded · Effective date not recorded

      Metabolites of atorvastatin are substrates of OATP1B1.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:09c6c750-ae05-459f-83e8-4a9e4fd85212 (opens source in a new tab)

      Atorvastatin label

      Version not recorded · Effective date not recorded

      Drug Interactions Atorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3 transporter.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:09c6c750-ae05-459f-83e8-4a9e4fd85212 (opens source in a new tab)

      Atorvastatin label

      Version not recorded · Effective date not recorded

      Metabolites of atorvastatin are substrates of OATP1B1.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=480

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy